Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

SELL
$0.28 - $0.64 $4,144 - $9,472
-14,800 Reduced 15.04%
83,600 $45,000
Q3 2023

Nov 14, 2023

SELL
$0.29 - $0.48 $8,555 - $14,160
-29,500 Reduced 23.06%
98,400 $29,000
Q2 2023

Aug 14, 2023

SELL
$0.28 - $0.79 $504 - $1,422
-1,800 Reduced 1.39%
127,900 $43,000
Q1 2023

May 15, 2023

SELL
$0.63 - $1.3 $53,802 - $111,020
-85,400 Reduced 39.7%
129,700 $102,000
Q4 2022

Feb 14, 2023

SELL
$0.86 - $22.2 $68,886 - $1.78 Million
-80,100 Reduced 27.13%
215,100 $215,000
Q3 2022

Nov 14, 2022

BUY
$0.83 - $17.8 $132,883 - $2.85 Million
160,100 Added 118.5%
295,200 $263,000
Q2 2022

Aug 15, 2022

BUY
$0.7 - $1.56 $27,720 - $61,776
39,600 Added 41.47%
135,100 $150,000
Q1 2022

May 16, 2022

BUY
$1.37 - $2.43 $116,039 - $205,821
84,700 Added 784.26%
95,500 $133,000
Q4 2021

Feb 14, 2022

SELL
$2.27 - $4.39 $258,326 - $499,581
-113,800 Reduced 91.33%
10,800 $25,000
Q3 2021

Nov 15, 2021

BUY
$3.37 - $4.76 $222,083 - $313,684
65,900 Added 112.27%
124,600 $520,000
Q2 2021

Aug 16, 2021

BUY
$4.75 - $9.39 $71,725 - $141,789
15,100 Added 34.63%
58,700 $279,000
Q1 2021

May 17, 2021

BUY
$4.59 - $9.04 $200,124 - $394,143
43,600 New
43,600 $363,000

Others Institutions Holding ONCT

About Oncternal Therapeutics, Inc.


  • Ticker ONCT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,517,200
  • Market Cap $29.4M
  • Description
  • Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a smal...
More about ONCT
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.